News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
UNITED LABORATORIES (03933.HK) Dupilumab Injection Receives Implied Approval for Clinical Trial
UNITED LABORATORIES (03933.HK) announced that the atopic dermatitis indication for the dupilumab biosimilar injection developed by its wholly owned subsidiary, Zhuhai United, has o...
Reset
Send
The window will close in 5 seconds
UNITED LABORATORIES (03933.HK) Dupilumab Injection Receives Implied Approval for Clinical Trial
Close
Recommend
2
Positive
3
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Gold ETF share!

UNITED LABORATORIES (03933.HK)  -0.170 (-1.793%)    Short selling $19.81M; Ratio 26.081%   announced that the atopic dermatitis indication for the dupilumab biosimilar injection developed by its wholly owned subsidiary, Zhuhai United, has obtained implied approval for clinical trials from the National Medical Products Administration of China. Dupilumab is a fully human immunoglobulin G4 monoclonal antibody used for the treatment of atopic dermatitis, particularly in patients with moderate-to-severe atopic dermatitis whose condition is inadequately controlled by topical therapies or for whom topical therapies are not advisable. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-15 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.